Stocktoria
Erasca, Inc. ERAS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-07-15
Erasca, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating income | -$140.9M | -$179.6M | -$141.5M | -$247.4M | -$124.9M | -$109.3M |
| Income tax | $0 | $0 | — | — | — | — |
| Net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M | -$122.8M | -$101.7M |
| EPS (diluted) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 | — |
| Operating cash flow | -$95.5M | -$109.4M | -$101.2M | -$103.3M | -$79.6M | -$32.7M |
| Free cash flow | -$95.6M | -$109.5M | -$103.0M | -$117.8M | -$90.8M | -$33.6M |
| Cash & equivalents | $73.8M | $67.7M | $93.1M | $284.2M | $360.5M | $65.4M |
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M | $124.8M |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M | $17.4M |
| Shareholders' equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M | -$114.0M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.